• News
  • North America

Arrow Ventures Backs Nutrivert Livestock Trials

Funding supports US pig studies of a non-antibiotic treatment

11/17/2026
•Ghita Khalfaoui
Back to News

Arrow Ventures has committed up to US$4.85 million to Nutrivert for US livestock trials. The funding will back studies involving 4,800 pigs in the US Midwest. Nutrivert is developing LDPP as a non-antibiotic alternative for swine production.


Trial design

The studies compare pigs receiving LDPP, antibiotics, both treatments, or neither. Researchers will measure weight gain, feed conversion efficiency, and overall mortality. The two trials are intended to account for differences in animal health and environmental conditions.

Company context

Arrow Ventures is a Singapore-based investor founded by Australian entrepreneur Nick Bova. It focuses on small veterinary medicine companies and has active investments in five animal health firms. Nutrivert has worked on LDPP for nearly a decade and holds patents in multiple markets.

How LDPP works

LDPP is a synthetic compound designed to mimic a component of bacterial cell walls. It does not kill bacteria or act as an antibacterial. It interacts with NOD2, a receptor in the immune response, and may support growth and feed efficiency without antibiotics.


Nutrivert still faces the standard development pathway for a veterinary medicine. Further trials and safety assessments will be required before commercialization. The company estimates FDA approval remains about three years away, subject to trial results, safety data, and regulatory requirements.